טוען...

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study

BACKGROUND: Recurrence of prior invasive fungal infection (relapse rate of 30–50%) limits the success of stem cell transplantation. Secondary prophylaxis could reduce disease burden and improve survival. DESIGN AND METHODS: A prospective, open-label, multicenter trial was conducted evaluating vorico...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Cordonnier, Catherine, Rovira, Montserrat, Maertens, Johan, Olavarria, Eduardo, Faucher, Catherine, Bilger, Karin, Pigneux, Arnaud, Cornely, Oliver A, Ullmann, Andrew J., Bofarull, Rodrigo Martino, de la Cámara, Rafael, Weisser, Maja, Liakopoulou, Effie, Abecasis, Manuel, Heussel, Claus Peter, Pineau, Marc, Ljungman, Per, Einsele, Hermann
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2010
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2948103/
https://ncbi.nlm.nih.gov/pubmed/20634495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.020073
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!